Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATH-1020 SAD/MAD in Healthy Volunteers
NCT05169671Phase 1Completed
- Sponsor
- LeonaBio
- Start
- Mar 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Neuropsychiatric disorders and neurodegenerative diseases comparing ATH-1020 with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Mar 2022; status: completed.
02
Drugs
ATH-1020
03
Conditions
Neuropsychiatric disordersneurodegenerative diseases
Beyond the preview
Go deeper on NCT05169671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05169671.